Mitogen-activated protein kinase kinase

From Proteopedia

Revision as of 12:21, 17 July 2019

spinqualitylabelsall models Human MAP2K1 complex with an anticancer agent, ATP and Mg+2 ion (PDB entry 3os3) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Contents 1 Function 2 Relevance 3 Disease 4 Structural highlights Function Mitogen-activated protein kinase kinase (MAP2K) are serine/threonine kinases which regulate various cellular activities in response to extracellular stimuli by mitogens, heat shock and more. MAP2K is part of the MAPK cascade which consists also of MAPK and MAP3K which are activated by phosphorylation. MAP2K activates MAPK[1],[2]. MAP2K1 slows down sister chromatid association in meiosis. MAP2K2 phosphorylates MAPK1 and MAPK2. MAP2K3 phosphorylates MAPK14. MAP2K4 phosphorylates MAPK8, MAPK9 and MAPK14. MAP2K5 phosphorylates MAPK7. MAP2K6 phosphorylates p38-MAPKs in response to stress. MAP2K7 phosphorylates MAPK8 and MAPK9. Relevance MAP2K is activated in melanoma and its inhibitors are tested as therapeutical agents[3]. Disease MAP2K4 mutations are seen in many types of cancer and particularly in breast cancer[4]. Structural highlights The biological assembly of Human MAP2K1 is . MAP2K inhibitors interact with the active site ATP[5]. . . . .

3D Structures of Mitogen-activated protein kinase kinase

Updated on 17-July-2019

References

1. ↑ Weyman CM, Wolfman A. Mitogen-activated protein kinase kinase (MEK) activity is required for inhibition of skeletal muscle differentiation by insulin-like growth factor 1 or fibroblast growth factor 2. Endocrinology. 1998 Apr;139(4):1794-800. PMID:9528964 doi:http://dx.doi.org/10.1210/endo.139.4.5950
2. ↑ Zheng CF, Guan KL. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem. 1993 Nov 15;268(32):23933-9. PMID:8226933
3. ↑ Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):782-9. doi: 10.1016/S1470-2045(12)70269-3. Epub 2012, Jul 16. PMID:22805292 doi:http://dx.doi.org/10.1016/S1470-2045(12)70269-3
4. ↑ Su GH, Song JJ, Repasky EA, Schutte M, Kern SE. Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat. 2002 Jan;19(1):81. PMID:11754110 doi:http://dx.doi.org/10.1002/humu.9002
5. ↑ Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K, Miura T, Yoshimura Y, Aida S, Miwa M, Saitoh R, Murao N, Okabe H, Belunis C, Janson C, Lukacs C, Schuck V, Shimma N. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg Med Chem Lett. 2011 Jan 21. PMID:21316218 doi:10.1016/j.bmcl.2011.01.062